 |
|
Clinical and Medication Outcome After Short-term Alprazolam and Behavorial Group Treatment in Panic Disorder2.5-Year Naturalistic Follow-up Study
Linda M. Nagy, MD;
John H. Krystal, MD;
Scott W. Woods, MD;
Dennis S. Charney, MD
Arch Gen Psychiatry. 1989;46(11):993-999.
Abstract
• Sixty patients with agoraphobia with panic attacks or panic disorder who completed a 4-month combined drug and behavioral group treatment program and were discharged on a regimen of alprazolam were interviewed 1.7 to 4 years (mean, 2.5 years) after discharge. At follow-up (FU), 18 (30%) of the patients had discontinued alprazolam treatment, 36 (60%) continued with a lower dose, 3 (5%) received the same dose, and 3 (5%) received an increased dose compared with discharge. A lower frequency of panic attacks at admission was associated with an increased ability to discontinue alprazolam treatment. There was little evidence of tolerance to the antipanic effects of alprazolam. Panic attack frequency dropped from a mean of 4.4 attacks per week at admission to 1.2 attacks per week at discharge and remained decreased at 1.6 attacks per week at FU. Treatment gains in the program were maintained or enhanced on 11 of 14 behavioral measures at FU and were similar in the groups that were receiving and not receiving alprazolam. Patients receiving nonpharmacologic therapy in the FU period tended to have greater symptom severity, possibly due to self-selection. A lifetime diagnosis of major depression at admission was associated with higher levels of depressive and anxiety symptoms and higher alprazolam doses at FU. Episodes of major depression were common in the FU period and did not appear to be prevented by initial alprazolam and behavioral therapy or by low-dose alprazolam maintenance. Further investigation is needed to determine whether patients with panic disorder who have current or a past history of major depression would be more appropriately treated with tricyclic antidepressants or monoamine oxidase inhibitors than with benzodiazepines.
Author Affiliations
From the Clinical Neuroscience Research Unit, Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, and the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn.
Footnotes
Accepted for publication February 13, 1989.
Reprint requests to Department of Psychiatry, Yale University School of Medicine, Veterans Administration Medical Center, Psychiatry Service 116/A, 950 Campbell Ave, West Haven, CT 06516. (Dr Nagy).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Australian and New Zealand Clinical Practice Guidelines for the Treatment of Panic Disorder and Agoraphobia
Royal Australian and New Zealand College Of Psychi
Aust N Z J Psychiatry 2003;37:641-656.
ABSTRACT
| FULL TEXT
A Pilot Open Trial of Brief Psychodynamic Psychotherapy for Panic Disorder
Milrod et al.
J. Psychother. Pract. Res. 2001;10:239-245.
ABSTRACT
| FULL TEXT
Maintenance Drug Treatment of Panic Disorder: I. Results of a Prospective, Placebo-Controlled Comparison of Alprazolam and Imipramine
Schweizer et al.
Arch Gen Psychiatry 1993;50:51-60.
ABSTRACT
Maintenance Drug Treatment for Panic Disorder: II. Short- and Long-term Outcome After Drug Taper
Rickels et al.
Arch Gen Psychiatry 1993;50:61-68.
ABSTRACT
Follow-up Study of Patients With Panic Disorder-Reply
Nagy et al.
Arch Gen Psychiatry 1991;48:861-862.
ABSTRACT
Follow-up Study of Patients With Panic Disorder
Judd et al.
Arch Gen Psychiatry 1991;48:860-861.
ABSTRACT
Panic Attacks in the Community: Social Morbidity and Health Care Utilization
Klerman et al.
JAMA 1991;265:742-746.
ABSTRACT
Treatment of Panic Disorder
Hayes
Journal of Pharmacy Practice 1990;3:233-240.
ABSTRACT
|
